National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 3) 2026

PB 71 of 2026

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 3) 2026

I, Rebecca Richardson, as delegate of the Minister for Health, Disability and Ageing, make the following Determination.

Dated 15 June 2026

Rebecca Richardson

Assistant Secretary
PBS Listing, Pricing and Policy Branch
Technology Assessment and Access Division
Department of Health, Disability and Ageing

Contents

1  Name

2  Commencement

3  Authority

4  Schedules

Schedule 1—Amendments—Additional designated brands effective from 1 November 2026

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023  2

Schedule 2—Amendments—Additional designated brands effective from 1 December 2026

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023 3

1  Name

 (1) This instrument is the National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 3) 2026.

 (2) This instrument may also be cited as PB 71 of 2026.

2  Commencement

 (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

  This instrument is made under subsection 99ADHC(2) of the National Health Act 1953.

4  Schedules

  Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments—Additional designated brands effective from 1 November 2026

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1  Section 5 (before table item dealing with the brand Ritalin 10 of the drug Methylphenidate in the form Tablet containing methylphenidate hydrochloride 10 mg)

Insert:

Schedule 2—Amendments—Additional designated brands effective from 1 December 2026

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1  Section 5 (before table item dealing with the brand Fosamax Plus 70 mg/140 mcg of the drug Alendronic acid with colecalciferol in the form Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol)

Insert:

2  Section 5 (after table item dealing with the brand Norimin 28 Day of the drug Norethisterone with ethinylestradiol in the form Pack containing 21 tablets 500 micrograms-35 micrograms and 7 inert tablets)

Insert: